Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

  • CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

Incidence of GBS and CIDP Following Influenza Vaccination
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
25:18 MIN
  • CIDP
  • GBS

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

DOWNLOAD PDF
Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
8:25 MIN
  • CIDP

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

DOWNLOAD PDF
Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
12:13 MIN
  • CIDP
Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients
DOWNLOAD PDF
Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

14:01 MIN
  • CIDP

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

DOWNLOAD PDF
NOW PLAYING
25:18
Incidence of GBS and CIDP Following Influenza Vaccination

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

NOW PLAYING
8:25
Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Th...

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

NOW PLAYING
12:13
Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabiliza...
Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients
NOW PLAYING
14:01
Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

Our Experts on CIDP

Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
  • CIDP
  • GBS
Dr. Harbo is a neuromuscular specialist at Aarhus University Hospital in Aarhus, Denmark, a certified Centre of Excellence by the GBS|CIDP Foundation International.
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
  • CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
Jeffrey A. Allen, MD
University of Minnesota
Jeffrey A. Allen, MD
University of Minnesota
  • CIDP
  • MMN
Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
Vera Bril, BSc, FRCPC, MD
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
  • CIDP
Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology.
What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?
READ MORE
What are the symptoms of CIDP?
READ MORE
How is CIDP treated?
READ MORE

Slides & Posters about CIDP

Clinical Studies for the Treatment of CIDP with Immunoglobulin
PDF | 396 KB
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-...
PDF | 3.8 MB
Pathogenesis and Mechanism of Action of Inflammatory Neuropathies
PDF | 680 KB
Fatigue in CIDP
PDF | 1.23 MB
Back to Top